Cover ImageSALE
市場調查報告書

失智症與異動症治療的全球市場:2017-2021年

Global Dementia and Movement Disorder Treatment Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 531739
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
Back to Top
失智症與異動症治療的全球市場:2017-2021年 Global Dementia and Movement Disorder Treatment Market 2017-2021
出版日期: 2017年07月19日 內容資訊: 英文 102 Pages
簡介

全球失智症和異動症治療的市場,預計從2017年到2021年以4.48%的年複合成長率發展。

本報告提供全球失智症和異動症治療的市場調查,疾病概要,開發平台趨勢,市場規模的變化與預測,各藥物類別、各地區的明細,市場成長的各種影響因素及市場趨勢分析,競爭環境,主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 分析範圍

第3章 調查手法

第4章 簡介

  • 市場概要

第5章 失智症:概要

  • 失智症
  • 疾病的流行病學
  • 失智症的各種類型
  • 失智症治療的醫療介入
  • 帕金森氏症和失智症

第6章 異動症:概要

  • 異動症
  • 異動症的原因

第7章 市場環境

  • 市場概要
  • 市場規模、預測
  • 波特的五力分析

第8章 開發平台

第9章 市場分析:各類藥物

  • MAO抑制劑
  • AChE抑制劑
  • 麩胺酸抑制劑
  • 其他

第10章 地區分析

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第11章 決策架構

第12章 成長推動因素、課題

  • 市場促進因素
  • 市場課題

第13章 市場趨勢

  • 生物標記的出現
  • 逆轉阿茲海默症造成的認知功能降低的基因治療的成長
  • 生命醫科學的進步

第14章 供應商環境

  • 競爭模式

第15章 主要供應商分析

  • Allergan
  • Eisai
  • Novartis
  • Teva Pharmaceutical Industries
  • 其他有力供應商

第16章 附錄

圖表

目錄
Product Code: IRTNTR13812

About Dementia and Movement Disorder Treatment

Dementia is a collective term for disorders characterized by progressive degeneration of the brain. It impairs memory and affects behavioral, emotional, and cognitive abilities. The neuronal death or neuronal malfunction associated with the disorder manifests as shifts in mood and personality changes, difficulty in performing activities, loss of memory, and aphasia. Dementia can be classified into different types, based on the parts of brain affected. Among these types, Alzheimer's disease is the most common type of dementia.

Technavio's analysts forecast the global dementia and movement disorder treatment market to grow at a CAGR of 4.48% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global dementia and movement disorder treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Dementia and Movement Disorder Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Allergan
  • Eisai
  • Novartis
  • Teva Pharmaceutical Industries

Other Prominent Vendors

  • Amgen
  • Pfizer
  • UCB
  • H. Lundbeck
  • F. Hoffmann-La Roche
  • Eli Lilly

Market driver

  • Need for disease modifying drugs (DMDs)
  • For a full, detailed list, view our report

Market challenge

  • Social stigma associated with dementia
  • For a full, detailed list, view our report

Market trend

  • Emergence of biomarkers
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: Dementia: An overview

  • Dementia
  • Epidemiology of disease
  • Types of dementia
  • Medical interventions to treat dementia
  • Parkinson's disease and dementia

PART 06: Movement disorder: An overview

  • Movement disorders
  • Cause of movement disorders

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Pipeline

PART 09: Segmentation by drug class

  • Global DAMD treatment market by MAO inhibitors
  • Global DAMD treatment market by AChE inhibitors
  • Global DAMD treatment market by glutamate inhibitors
  • Global DAMD treatment market by others

PART 10: Geographical segmentation

  • DAMD treatment market in Americas
  • DAMD treatment market in EMEA
  • DAMD treatment market in APAC

PART 11: Decision framework

PART 12: Drivers and challenges

  • Market drivers
  • Market challenges

PART 13: Market trends

  • Emergence of biomarkers
  • Growth of gene therapy to reverse cognitive decline associated with Alzheimer's disease
  • Advances in biomedical science

PART 14: Vendor landscape

  • Competitive scenario

PART 15: Key vendor analysis

  • Allergan
  • Eisai
  • Novartis
  • Teva Pharmaceutical Industries
  • Other prominent vendors

PART 16: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Functions of brain affected by dementia
  • Exhibit 02: Types of Alzheimer's disease
  • Exhibit 03: Cognitive impairment in dementia
  • Exhibit 04: Types of dementia
  • Exhibit 05: Types of dementia by prevalence rate 2006
  • Exhibit 06: Vendor initiative in DAMD treatment market
  • Exhibit 07: Types of movement disorders
  • Exhibit 08: Insufficient movement disorders
  • Exhibit 09: Excessive movement disorders
  • Exhibit 10: Cause of movement disorder
  • Exhibit 11: Market segmentation by drug class 2016
  • Exhibit 12: Market snapshot: Global DAMD treatment market
  • Exhibit 13: Global DAMD treatment market 2016-2021 ($ millions)
  • Exhibit 14: Opportunity analysis of global DAMD treatment market
  • Exhibit 15: Five forces analysis
  • Exhibit 16: Pipeline landscape based on number of molecules 2016
  • Exhibit 17: Alzheimer's disease: Key clinical trials
  • Exhibit 18: Huntington's disease: Key clinical trials
  • Exhibit 19: Parkinson's disease: Key clinical trials
  • Exhibit 20: Global DAMD treatment market by drug class
  • Exhibit 21: Global DAMD treatment market by drug-class 2016
  • Exhibit 22: Global DAMD treatment market by MAO inhibitors 2016-2021 ($ millions)
  • Exhibit 23: Global DAMD treatment market by AChE inhibitors 2016-2021 ($ millions)
  • Exhibit 24: Global DAMD treatment market by glutamate inhibitors 2016-2021 ($ millions)
  • Exhibit 25: Global DAMD treatment market by others 2016-2021 ($ millions)
  • Exhibit 26: Global DAMD treatment market by geography 2016 and 2021
  • Exhibit 27: Global DAMD treatment market by geography 2016-2021 ($ millions)
  • Exhibit 28: Global DAMD treatment market by geography 2016-2021
  • Exhibit 29: DAMD treatment market scenario in different regions
  • Exhibit 30: Market scenario in Americas
  • Exhibit 31: DAMD treatment market in Americas 2016-2021 ($ millions)
  • Exhibit 32: Market scenario in EMEA
  • Exhibit 33: DAMD treatment market in EMEA 2016-2021 ($ millions)
  • Exhibit 34: Market scenario in APAC
  • Exhibit 35: DAMD treatment market in APAC 2016-2021 ($ millions)
  • Exhibit 36: Prevalence rate of dementia 2006
  • Exhibit 37: Geriatric population analysis by geography in 2000 and estimates for 2030
  • Exhibit 38: Death rate per 100,000 in US population due to Alzheimer's disease 2010-2014
  • Exhibit 39: Revenue erosion of Aricept after loss of exclusivity
  • Exhibit 40: Competitive structure analysis of global DAMD treatment market 2016
  • Exhibit 41: Allergan: Key highlights
  • Exhibit 42: Allergan: Strength assessment
  • Exhibit 43: Allergan: Strategy assessment
  • Exhibit 44: Allergan: Opportunity assessment
  • Exhibit 45: Eisai: Key highlights
  • Exhibit 46: Eisai: Strength assessment
  • Exhibit 47: Eisai: Strategy assessment
  • Exhibit 48: Eisai: Opportunity assessment
  • Exhibit 49: Novartis: Key highlights
  • Exhibit 50: Novartis: Strength assessment
  • Exhibit 51: Novartis: Strategy assessment
  • Exhibit 52: Novartis: Opportunity assessment
  • Exhibit 53: Teva Pharmaceutical Industries: Pipeline molecules for treatment of neurodegenerative disorders
  • Exhibit 54: Teva Pharmaceutical Industries: Key highlights
  • Exhibit 55: Teva Pharmaceutical Industries: Strength assessment
  • Exhibit 56: Teva Pharmaceutical Industries: Strategy assessment
  • Exhibit 57: Teva Pharmaceutical Industries: Opportunity assessment
Back to Top